[go: up one dir, main page]

WO2019017680A3 - Micro-arn utilisé en tant que biomarqueur de la maladie de parkinson et kit diagnostique le mettant en oeuvre - Google Patents

Micro-arn utilisé en tant que biomarqueur de la maladie de parkinson et kit diagnostique le mettant en oeuvre Download PDF

Info

Publication number
WO2019017680A3
WO2019017680A3 PCT/KR2018/008085 KR2018008085W WO2019017680A3 WO 2019017680 A3 WO2019017680 A3 WO 2019017680A3 KR 2018008085 W KR2018008085 W KR 2018008085W WO 2019017680 A3 WO2019017680 A3 WO 2019017680A3
Authority
WO
WIPO (PCT)
Prior art keywords
parkinson
disease
mirna
biomarker
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2018/008085
Other languages
English (en)
Korean (ko)
Other versions
WO2019017680A9 (fr
WO2019017680A2 (fr
Inventor
류현정
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kookmin University
Original Assignee
Kookmin University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020170116583A external-priority patent/KR101956315B1/ko
Priority to CN202510050435.5A priority Critical patent/CN119979693A/zh
Priority to US16/631,954 priority patent/US11447772B2/en
Priority to CN202410767998.1A priority patent/CN118516457A/zh
Priority to EP18834700.9A priority patent/EP3656876A4/fr
Priority to CN201880059124.3A priority patent/CN111344417B/zh
Application filed by Kookmin University filed Critical Kookmin University
Priority to JP2020502648A priority patent/JP7030358B2/ja
Publication of WO2019017680A2 publication Critical patent/WO2019017680A2/fr
Publication of WO2019017680A3 publication Critical patent/WO2019017680A3/fr
Publication of WO2019017680A9 publication Critical patent/WO2019017680A9/fr
Anticipated expiration legal-status Critical
Priority to US17/888,084 priority patent/US20220389426A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne une méthode destinée à fournir des informations sur le diagnostic de la maladie de Parkinson. L'invention concerne également une composition destinée à prévenir, atténuer ou traiter la maladie de Parkinson. Le micro-ARN selon l'invention peut être utilisé efficacement dans le diagnostic et le traitement de la maladie de Parkinson étant donné qu'il présente une expression régulée spécifiquement à la baisse ou à la hausse dans un modèle de maladie de Parkinson.
PCT/KR2018/008085 2017-07-19 2018-07-17 Micro-arn utilisé en tant que biomarqueur de la maladie de parkinson et kit diagnostique le mettant en oeuvre Ceased WO2019017680A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2020502648A JP7030358B2 (ja) 2017-07-19 2018-07-17 パーキンソン病バイオマーカーとしてのｍｉＲＮＡ及びこれを用いた診断キット
US16/631,954 US11447772B2 (en) 2017-07-19 2018-07-17 miRNA as biomarker for Parkinson's disease and diagnostic kit using same
CN202410767998.1A CN118516457A (zh) 2017-07-19 2018-07-17 作为帕金森病生物标记物的miRNA及利用其的诊断试剂盒
EP18834700.9A EP3656876A4 (fr) 2017-07-19 2018-07-17 Micro-arn utilisé en tant que biomarqueur de la maladie de parkinson et kit diagnostique le mettant en oeuvre
CN201880059124.3A CN111344417B (zh) 2017-07-19 2018-07-17 作为帕金森病生物标记物的miRNA及利用其的诊断试剂盒
CN202510050435.5A CN119979693A (zh) 2017-07-19 2018-07-17 作为帕金森病生物标记物的miRNA及利用其的诊断试剂盒
US17/888,084 US20220389426A1 (en) 2017-07-19 2022-08-15 miRNA AS BIOMARKER FOR PARKINSON'S DISEASE AND DIAGNOSTIC KIT USING SAME

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
KR20170091417 2017-07-19
KR10-2017-0091417 2017-07-19
KR1020170116583A KR101956315B1 (ko) 2017-07-19 2017-09-12 파킨슨병 바이오마커로서의 miR494 및 이를 이용한 진단키트
KR10-2017-0116583 2017-09-12
KR1020170132869A KR101956329B1 (ko) 2017-07-19 2017-10-12 파킨슨병 바이오마커로서의 miR4726 및 이를 이용한 진단키트
KR1020170132867A KR101956323B1 (ko) 2017-07-19 2017-10-12 파킨슨병 바이오마커로서의 miR6768 및 이를 이용한 진단키트
KR1020170132868A KR101956328B1 (ko) 2017-07-19 2017-10-12 파킨슨병 바이오마커로서의 miR4324 및 이를 이용한 진단키트
KR1020170132866A KR102063244B1 (ko) 2017-07-19 2017-10-12 파킨슨병 바이오마커로서의 miR1244 및 이를 이용한 진단키트
KR10-2017-0132867 2017-10-12
KR10-2017-0132868 2017-10-12
KR10-2017-0132866 2017-10-12
KR10-2017-0132870 2017-10-12
KR10-2017-0132869 2017-10-12
KR1020170132870A KR102062787B1 (ko) 2017-07-19 2017-10-12 파킨슨병 바이오마커로서의 miR501 및 이를 이용한 진단키트

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/631,954 A-371-Of-International US11447772B2 (en) 2017-07-19 2018-07-17 miRNA as biomarker for Parkinson's disease and diagnostic kit using same
US17/888,084 Continuation US20220389426A1 (en) 2017-07-19 2022-08-15 miRNA AS BIOMARKER FOR PARKINSON'S DISEASE AND DIAGNOSTIC KIT USING SAME

Publications (3)

Publication Number Publication Date
WO2019017680A2 WO2019017680A2 (fr) 2019-01-24
WO2019017680A3 true WO2019017680A3 (fr) 2019-04-18
WO2019017680A9 WO2019017680A9 (fr) 2019-05-16

Family

ID=65015773

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/008085 Ceased WO2019017680A2 (fr) 2017-07-19 2018-07-17 Micro-arn utilisé en tant que biomarqueur de la maladie de parkinson et kit diagnostique le mettant en oeuvre

Country Status (1)

Country Link
WO (1) WO2019017680A2 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014018650A1 (fr) * 2012-07-25 2014-01-30 Rush University Medical Center Miarn en tant que nouvelles cibles thérapeutiques et biomaqueurs de diagnostic pour la maladie de parkinson
WO2014075822A1 (fr) * 2012-11-16 2014-05-22 Siemens Aktiengesellschaft Nouveaux marqueurs de miarn de diagnostic de la maladie de parkinson
US9297007B2 (en) * 2010-05-28 2016-03-29 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg miRNAs involved in the blood brain barrier function
US20170044529A1 (en) * 2012-12-18 2017-02-16 University Of Washington Through Its Center For Commercialization Methods and Compositions to Modulate RNA Processing
WO2017084770A1 (fr) * 2015-11-20 2017-05-26 Braindtech S.R.L. Procédés à base de microarn contenu dans des microvésicules microgliales pour le diagnostic, le pronostic et le suivi du traitement de maladies neurologiques, neurodégénératives et inflammatoires

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4437975A (en) 1977-07-20 1984-03-20 Mobil Oil Corporation Manufacture of lube base stock oil
US5242794A (en) 1984-12-13 1993-09-07 Applied Biosystems, Inc. Detection of specific sequences in nucleic acids
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
IL86724A (en) 1987-06-19 1995-01-24 Siska Diagnostics Inc Methods and kits for amplification and testing of nucleic acid sequences
CA1340843C (fr) 1987-07-31 1999-12-07 J. Lawrence Burg Amplification selective de sequences polynucleotidiques cibles
EP0359789B1 (fr) 1988-01-21 1993-08-04 Genentech, Inc. Amplification et detection de sequences d'acides nucleiques
CA1340807C (fr) 1988-02-24 1999-11-02 Lawrence T. Malek Procede d'amplification d'une sequence d'acide nucleique
US4988617A (en) 1988-03-25 1991-01-29 California Institute Of Technology Method of detecting a nucleotide change in nucleic acids
JP2955759B2 (ja) 1988-07-20 1999-10-04 セゲブ・ダイアグノスティックス・インコーポレイテッド 核酸配列を増幅及び検出する方法
KR0148265B1 (ko) 1988-12-16 1998-10-15 에프.지이.엠 헤르만스 자가-지속 서열 복제 시스템
ES2089038T3 (es) 1990-01-26 1996-10-01 Abbott Lab Procedimiento mejorado para amplificar acidos nucleicos blanco aplicable para la reaccion en cadena de polimerasa y ligasa.
US5494810A (en) 1990-05-03 1996-02-27 Cornell Research Foundation, Inc. Thermostable ligase-mediated DNA amplifications system for the detection of genetic disease

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9297007B2 (en) * 2010-05-28 2016-03-29 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg miRNAs involved in the blood brain barrier function
WO2014018650A1 (fr) * 2012-07-25 2014-01-30 Rush University Medical Center Miarn en tant que nouvelles cibles thérapeutiques et biomaqueurs de diagnostic pour la maladie de parkinson
WO2014075822A1 (fr) * 2012-11-16 2014-05-22 Siemens Aktiengesellschaft Nouveaux marqueurs de miarn de diagnostic de la maladie de parkinson
US20170044529A1 (en) * 2012-12-18 2017-02-16 University Of Washington Through Its Center For Commercialization Methods and Compositions to Modulate RNA Processing
WO2017084770A1 (fr) * 2015-11-20 2017-05-26 Braindtech S.R.L. Procédés à base de microarn contenu dans des microvésicules microgliales pour le diagnostic, le pronostic et le suivi du traitement de maladies neurologiques, neurodégénératives et inflammatoires

Also Published As

Publication number Publication date
WO2019017680A9 (fr) 2019-05-16
WO2019017680A2 (fr) 2019-01-24

Similar Documents

Publication Publication Date Title
WO2016168784A3 (fr) Nanoparticules d'arn et procédé d'utilisation de celles-ci
MY206230A (en) Amyloid precursor protein (app) rnai agent compositions and methods of use thereof
MX2019015580A (es) Metodos para tratar la enfermedad de huntington.
MX2019015578A (es) Metodos para tratar la enfermedad de huntington.
WO2015092020A3 (fr) Utilisations des longs arn non codants pour le diagnostic, le pronostic et le traitement des cardiopathies et dans le cadre de la médecine régénérative
WO2019006005A3 (fr) Procédés et compositions pour le traitement du mélanome
MA39033A1 (fr) Formes solides d'acide {[5-(3-chlorophényl)-3-hydroxypyridine-2-carbonyl] amino}acétique, compositions et leurs utilisations
WO2017100726A8 (fr) Méthodes de traitement de la maladie de huntington
WO2017031067A3 (fr) Biomarqueurs pour le traitement de la pelade
WO2016044189A8 (fr) Méthodes de traitement du cancer faisant appel à un antagoniste se liant à l'axe pd-1 et à des antagonistes se liant à l'il-17
MX2012011543A (es) Tratamiento de sarcoidosis empleando celulas madre placentarias.
WO2005116250A8 (fr) Arnmi viraux ou associes aux virus et leur utilisation
BR112015023797A2 (pt) proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17
HK1253769A1 (zh) 用於诊断和治疗肾上腺脑白质营养不良的方法和组合物
TR201904514T4 (tr) Makrosiklik LRRK2 kinaz inhibitörleri.
EP4349408A3 (fr) Méthodes de traitement de protéinopathies
WO2019040106A3 (fr) Composés, sels associés et méthodes pour le traitement de maladies
WO2019055968A3 (fr) Marqueurs de santé végétale
WO2019067405A3 (fr) Formulation de fenfluramine compatible avec un régime cétogène
CA3010708A1 (fr) Procedes d'administration d'hepcidine
EP4574832A3 (fr) Promédicaments de dantrolène et leurs procédés d'utilisation
WO2019175260A3 (fr) Oligonucléotides modifiés et méthodes d'utilisation dans les tauopathies
ZA202000680B (en) Obinutuzumab treatment of a dlbcl patient subgroup
CN113038946A8 (zh) 用生物素组合物治疗自闭症和自闭症谱系障碍
MX384262B (es) Gel intestinal de levodopa y carbidopa y metodos de uso.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18834700

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2020502648

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018834700

Country of ref document: EP

Effective date: 20200219

WWG Wipo information: grant in national office

Ref document number: 201880059124.3

Country of ref document: CN